Loading...
Cingulate Inc.
CING•NASDAQ
HealthcareBiotechnology
$3.33
$-0.29(-8.01%)
Cingulate Inc. (CING) Stock Overview
Explore Cingulate Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-1.93
↑ 33.95%
EPS Growth
$-1.93
↑ 97.18%
Operating Margin
0.00%
↑ 31.26%
ROE
-473.25%
↑ 33.95%
Dividend Yield
0.00%
Analyst Recommendations
Strong Buy
0
Buy
3
Hold
0
Sell
0
Strong Sell
0
Price Targets
Low$0.00
Average$0.00
High$0.00
Company Profile
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
CEO
Dr. Shane J. Schaffer Pharm.D.
Employees
13
Headquarters
1901 West 47th Place, Kansas City, KS
Founded
2021